Archive, page 5
Source-linked news on obesity medications and weight-loss surgery.
Search the news archive
Explore: Insurance · Safety · Revision surgery
Older briefs
Page 5
-
Three studies separate weight regain after stopping from two active maintenance strategies
A BMJ meta-analysis estimated regain after weight-management medicines ended, while ATTAIN-MAINTAIN tested a switch to oral orforglipron and SURMOUNT-MAINTAIN tested continued or reduced-dose tirzepatide.
-
SURMOUNT‑MAINTAIN compares maximum‑tolerated, 5 mg, and withdrawn tirzepatide after initial loss
After 60 weeks of open-label tirzepatide, continuing the maximum tolerated dose preserved the largest average weight reduction, 5 mg had an intermediate result, and switching to placebo led to more regain through week 112.
-
Bariatric surgery led incretin drugs in ASMBS comparisons
Meeting abstracts comparing metabolic surgery with incretin drugs report larger one-year weight change and higher remission rates, plus better long-term heart and kidney signals in older adults.
-
Prior GLP‑1 use did not blunt bariatric surgery weight loss
ASMBS-presented Epic Cosmos data show people who took semaglutide or tirzepatide before bypass or sleeve still reached large total losses after the operation.
-
Bariatric surgery linked to fewer kidney failures and deaths
A TriNetX comparison of more than 8,900 people with obesity and chronic kidney disease was presented May 5, 2026 in San Antonio.
-
Two‑year GLP‑1 claims cost more than sleeve or bypass
Mayo Clinic Florida and Baylor researchers compared matched STATinMED claims in people with obesity and type 2 diabetes.
-
ASMBS meeting data show rising GLP‑1 use, falling operations, and a large treatment gap
One ASMBS meeting analysis found that 90% to 95% of patients whose records showed severe obesity without diabetes received neither treatment studied.
-
Ozempic tablets launch for adults with type 2 diabetes, not for weight management
Three Ozempic tablet strengths launched in May 2026.
-
Small OCULUS trial finds less retained stomach content after holding one GLP‑1 dose
In a 60-person randomized trial stopped early, a clinically significant gastric-content endpoint occurred in 3.1% of participants who held one dose and 25.0% who continued treatment before elective upper endoscopy.
-
Review links GLP‑1 medicines to a small absolute increase in a rare eye condition
Across 15 longitudinal studies involving more than 1.5 million people, GLP-1 use was associated with higher odds of NAION.
-
HISTORI analysis finds improved insulin sensitivity with semaglutide over 30 weeks
A secondary analysis of the 154-person HISTORI trial found better fasting glucose, insulin sensitivity, and insulin resistance measures with semaglutide.
-
FDA proposed keeping three GLP‑1 ingredients off the 503B bulks list
FDA proposed not adding semaglutide, tirzepatide, or liraglutide to the list of bulk substances available for 503B outsourcing-facility compounding.
-
Viking's Two Phase 3 Trials of Injectable VK2735 Finish Enrolling; Tablet Version Aims for Phase 3 in Late 2026
Viking Therapeutics, a San Diego biotech, used its April 29, 2026 quarterly update to report that both late-stage trials of its injectable obesity drug candidate, VK2735, have finished enrolling patients.
-
CMS delayed Medicare BALANCE for 2027 and extended the GLP‑1 Bridge
On April 21, 2026, CMS said the Medicare Part D portion of BALANCE would not start in 2027.
-
Review links prior bariatric surgery to more fluid or blood collections after tummy tucks
A meta-analysis of 27 observational studies found higher pooled odds of seroma and hematoma after abdominoplasty among patients with prior bariatric surgery.
-
GLP‑1 use linked to fewer new cases of an irregular heart rhythm
In a single-center retrospective cohort, GLP-1 treatment was associated with a lower adjusted hazard of new atrial fibrillation than matched control care.
-
ACHIEVE‑4 topline report finds orforglipron noninferior to insulin glargine for MACE‑4
Lilly reported that daily oral orforglipron met the ACHIEVE-4 cardiovascular noninferiority objective versus insulin glargine.
-
OBSCORE model estimates 10‑year risk across 18 obesity‑related outcomes
Researchers built a 20-feature model using UK Biobank data and tested parts of it in two independent cohorts.
-
Medicaid coverage for GLP‑1 obesity treatment remains a state‑by‑state decision
KFF counted 13 fee-for-service Medicaid programs covering GLP-1 medicines for obesity in January 2026.
-
Small trial tests semaglutide alongside therapy for alcohol use disorder
In a 108-person randomized trial, heavy-drinking days decreased more with semaglutide plus cognitive behavioral therapy than with placebo plus therapy over 26 weeks.
-
Foundayo's FDA Approval Letter Shows an Unusually Long List of Required Safety Studies
Eli Lilly's orforglipron, sold as Foundayo, was approved by the FDA on April 1, 2026 under application number 220934 for chronic weight management in adults with obesity, and in adults with overweight who also have at least one weight-related condition.
-
Review ranks average weight loss across tirzepatide, semaglutide, and liraglutide trials
A network meta-analysis of 15 phase 3 trials in adults without type 2 diabetes ranked higher tirzepatide regimens above semaglutide 2.4 mg and liraglutide 3 mg for average weight reduction.
-
FDA approves once‑daily Foundayo tablets for chronic weight management
Foundayo, orforglipron, is a once-daily GLP-1 tablet approved for eligible adults alongside reduced-calorie eating and increased activity.
-
Wegovy subscription announcement ties lower monthly prices to longer self‑pay terms
Novo Nordisk announced three-, six-, and 12-month Wegovy subscriptions for eligible self-pay patients through selected telehealth providers.
-
Review links bariatric surgery to improvements in fatty liver disease and diabetes
A meta-analysis of 29 studies and 71,904 patients estimated improvement in steatohepatitis, fibrosis, and type 2 diabetes after metabolic and bariatric surgery.
About this publication
Reporting standards and transparency
How we report
Obesity Treatment News is a BariatricPal publication. We review the linked source material, explain what changed, and state what the evidence does not establish.
Corrections
Send factual corrections through Contact BariatricPal. Material corrections are dated and noted in the article.
Ownership and commerce
BariatricPal owns OTN and the BariatricPal Store. Pages may include clearly separated advertising or store links. Commerce does not change the source summary.
About BariatricPal · Brief author · Contact · Weight-loss medications · Weight-loss surgery